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Tumor Biology and Immunology
Extracellular Matrix Protein Tenascin C Increases
Phagocytosis Mediated by CD47 Loss of Function
in Glioblastoma
Ding Ma1,2, Senquan Liu3, Bachchu Lal1,2, Shuang Wei1,2, Shuyan Wang1,2, Daqian Zhan1,2,
Hao Zhang4, Richard S. Lee5, Peisong Gao6, Hernando Lopez-Bertoni1,2, Mingyao Ying1,2,
Jian Jian Li7, John Laterra1,2,8,9, Mary Ann Wilson1,2, and Shuli Xia1,2
Abstract
Glioblastomas (GBM) are highly inﬁltrated by myeloid-
derived innate immune cells that contribute to the immuno-
suppressive nature of the brain tumor microenvironment
(TME). CD47 has been shown to mediate immune evasion,
as the CD47–SIRPa axis prevents phagocytosis of tumor cells
by macrophages and other myeloid cells. In this study, we
established CD47 homozygous deletion (CD47/) in
human and mouse GBM cells and investigated the impact of
eliminating the "don't eat me" signal on tumor growth and
tumor–TME interactions. CD47 knockout (KO) did not sig-
niﬁcantly alter tumor cell proliferation in vitro but signiﬁcantly
increased phagocytosis of tumor cells by macrophages in
cocultures. Compared with CD47wild-type xenografts, ortho-
topic xenografts derived from CD47/ tumor cells grew
signiﬁcantly slower with enhanced tumor cell phagocytosis
and increased recruitment ofM2-like tumor-associatedmicro-
glia/macrophages (TAM). CD47 KO increased tumor-associ-
ated extracellular matrix protein tenascin C (TNC) in xeno-
grafts, which was further examined in vitro. CD47 loss of
function upregulated TNC expression in tumor cells via a
Notch pathway–mediated mechanism. Depletion of TNC in
tumor cells enhanced the growth of CD47/ xenografts in vivo
and decreased the number of TAM. TNC knockdown also
inhibited phagocytosis of CD47/ tumor cells in cocultures.
Furthermore, TNC stimulated release of proinﬂammatory
factors including TNFa via a Toll-like receptor 4 and STAT3-
dependent mechanism in human macrophage cells. These
results reveal a vital role for TNC in immunomodulation in
brain tumor biology and demonstrate the prominence of the
TME extracellularmatrix in affecting the antitumor function of
brain innate immune cells.
Signiﬁcance: These ﬁndings link TNC to CD47-driven
phagocytosis and demonstrate that TNC affects the antitumor
function of brain TAM, facilitating the development of novel
innate immune system–based therapies for brain tumors.
Introduction
Gliomas account for 70% of all adult brain tumors. Grade IV
astrocytoma, glioblastoma (GBM), is the most common and
aggressive primary brain tumor, accounting for approximately
50% of all glial tumor types. Because of tumor heterogeneity
and the blood–brain barrier, GBM remains refractory to current
treatment modalities including surgery, radiotherapy, and che-
motherapy; the median survival time of patients with GBM is
approximately 15 to 20 months (1). Recent progress in immu-
notherapy-based treatment options in other tumor types has
encouraged interest in developing similar approaches that might
be effective for this devastating malignancy (2). However, current
immunotherapies have not yet improved the survival of GBM
patients (3). Understanding how tumor interacts with brain
immune systems, including the innate immune system, and
developing improved therapeutic options for GBM are urgently
needed.
Innate immune cells, such as microglia, macrophages, and
myeloid-derived suppressor cells, are known to be present within
GBM. Tumor-associated microglia/macrophages (TAM) contrib-
ute to 30% to 50%of brain tumormass (4, 5) and are educated by
tumor cells to acquire a tumor-promotingM2-like phenotype that
is able to produce anti-inﬂammatory and immune-suppressive
factors in the tumor microenvironment (TME). In GBMs, TAMs
with different phenotypes coexist, including an antitumor, proin-
ﬂammatory M1-like phenotype. The activation status rather than
the abundance of TAMs present in the TME has been shown to
have prognostic value (6).
TME can inﬂuence the properties of TAMs (7). Extracellular
matrix (ECM) is an important component of the TME and is
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composed of a complex mixture of macromolecules including
glycoproteins, proteoglycans, and polysaccharides. A body of
evidence indicates that in addition to their canonical role in
maintaining and regulating tissue organization, ECM compo-
nents function as signaling molecules by interacting with mem-
brane-bound receptors to regulate cell growth, motility, and
immune response (8). Although tightly controlled during embry-
onic development and organ homeostasis, these ECM-mediated
pathways are commonly deregulated and disorganized in cancer.
How ECM regulates immune response of brain tumors is largely
unknown.
In this study, we usedCD47 knockout (KO) human andmouse
glioma models to investigate how ECM modulates the interac-
tions between brain tumor cells and the innate immune system.
CD47, also known as integrin-associated protein, is a ubiquitous
50 kDa membrane-bound protein consisting of a single N-termi-
nal IgV extracellular domain, ﬁve membrane-spanning segments,
and a short C-terminal cytoplasmic tail (9). CD47 has been
reported to mediate immune evasion by interacting with the
signal regulatory protein-alpha (SIRPa) expressed on macro-
phages and other myeloid cells (10). CD47 binding to SIRPa
causes phosphorylation of the SIRPa cytoplasmic immunorecep-
tor tyrosine-based inhibitionmotifs, leading to the recruitment of
Src homology 2 domain–containing tyrosine phosphatases,
which prevents myosin-IIA accumulation at the phagocytic syn-
apse and consequently inhibits phagocytosis (11). Thus, the
CD47–SIRPa axis, also known as a "don't eat me" signal, func-
tions as a negative checkpoint for innate immunity. CD47 expres-
sion is elevated in many cancers; The Cancer Genome Atlas data
analysis indicated that high CD47 expression in GBM correlates
with poor patient survival (12). Blocking the CD47/SIRPa inter-
action facilitates phagocytosis and inhibits tumor growth inmany
preclinical cancer models (12, 13); for example, the administra-
tion of anti-CD47 mAbs reduced tumor growth and prevented
lung cancer progression (14).
Abundant evidence supports that the signaling functions of
CD47 gowell beyond this passive antiphagocytic role, with CD47
acting as a sensor for cell–microenvironment signals. As an
example,CD47 interactswithother signalingmolecules including
thematricellular glycoprotein thrombospondin-1 (TSP-1; refs. 15,
16) to regulate various cellular functions including cellmigration,
axonextension, cytokineproduction, andT-cell activation(17–19).
Therefore, it is critical to dissect the signaling network of CD47 in
tumor cells and tumor cell–immune cell interactions. The current
study in GBMmodels is aimed to understand how TME inﬂuences
host response to tumor cells carrying CD47 KO. We found that
CD47 KO dramatically increased tumor-associated ECM protein
tenascin C (TNC) in vitro and in vivo. Our results demonstrate the
importance of the ECM protein in the antitumor function of brain
innate immune cells.
Materials and Methods
Reagents and cell cultures
All reagents were purchased from MilliporeSigma unless oth-
erwise stated.HumanGBMcellsU87,mouse glioma cellsGL-261,
and human monocyte cells THP-1 were original purchased from
the ATCC. All cell lines are free from Mycoplasma and authenti-
cated with short tandem repeat proﬁling by Johns Hopkins
Genetic Resources Core facility using Promega GenePrint 10
system.
Generation of CD47 KO cell lines by CRISPR-Cas9 system
Cas9-GFP plasmid was purchased from Addgene. For targeting
CD47, two gRNAs targeting CD47 were cloned into pX330M
(Addgene) according to the addgene cloning protocol. Human
CD47 gRNA targeting sequences were: 50-CGACCGCCGCCG
CGCGTCACAGG (intron) and 50-CAGCAACAGCGCCGCTAC-
CAGGG (ﬁrst exon). Mouse CD47 gRNA targeting sequences
were: 50-cccttgcatcgtccgtaatgtgg (intron) and 50-cagtagttttctttacgt-
taagg (ﬁrst exon). Glioma cells (2  105 per well in 6-well plate)
were cotransfected with the two gRNA plasmids and Cas9-GFP
using lipofectamine 3000. After 2 days, transfected cells were
sorted by ﬂow cytometry (GFPþ) and subcloned. Genomic DNA
was extracted from clonal cells and ampliﬁed using the primer set
as follows: for human: forward: 50-GTCTGGAGCCTGCGACTG;
reverse: 50-GTGTGTGCATTTGGAGATGG; for mouse: forward: 50-
gtctactggctggtgtgcaa; reverse: 50-catcgcgcttatccattttc. Sanger
sequencing of the PCR products was performed to screen CD47
genomic KO.
Preparationof cell lineswithTNCknockdownusing shRNAand
lentivirus system
To knock down TNC expression, lentivirus containing a control
nonsilencing (NS) sequence or TNC shRNA in a GIPZ viral vector
(Thermo Fisher Scientiﬁc) containing the GFP coding frame was
introduced into cells (20).
Cell migration assay
Migration was quantiﬁed by Boyden chamber transwell assays
(8-mm pore size; Corning Costar) following our published
work (21, 22).
Quantitative real-time PCR
Total RNA was extracted using the RNeasy Mini Kit (Qiagen).
After reverse transcription using cDNA reverse transcriptase
(Applied Biosystems) and Oligo(dT) primer, quantitative real-
time PCR (qRT-PCR) was performed using SYBR Green PCR Mix
(Applied Biosystems) and IQ5 detection system (Bio-Rad). Prim-
er sequences used in this studywere listed in Supplementary Table
S1. Relative gene expression was normalized to GAPDH.
Immunoblot
Proteins were detected and quantiﬁed using the Odyssey Infra-
red Imager (LI-COR Biosciences) with secondary antibodies
labeled by IRDye infrared dyes (LI-COR Biosciences) and nor-
malized toGAPDHor b-actin following our publishedwork (20).
The antibodies used for this studywere listed below,most of them
from Cell Signaling Technology unless otherwise stated: CD47
(Santa Cruz Biotechnology); TNC (mouse and human, Millipor-
eSigma); TNC (human only, Santa Cruz Biotechnology); STAT-3;
phospho-STAT-3; Akt; phosphor-Akt; Jagged-1; NOTCH1; NICD;
b-actin (MilliporeSigma); GAPDH (MilliporeSigma).
ELISA of TNFa
Humanmonocyte cells THP-1 were seeded onto 12-well plates
(1.5  105/well) and incubated with phorbol 12-myristate
13-acetate (PMA, 25 ng/mL) for 48 hours to introduce differen-
tiation. Cells were treated with TNC protein at 1, 3, and 10 mg/mL
for another 8 hours in serum-free medium, and the supernatant
was collected for TNFa measurement using a TNFa ELISA kit
(R&D Systems). TNC was purchased from Millipore and puriﬁed
from the conditioned medium of human U251 GBM cell line by
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chromatography. All measurements were conducted according to
the manufacturer's protocol using a microplate spectrophotom-
eter (Molecular Devices). For some experiments, cells were incu-
bated with STAT3 inhibitor (Stattic, 5 mmol/L) or TLR-4 inhibitor
(TAK242, 10 mmol/L) for 1 hour prior to TNC treatment.
In vitro phagocytosis assay
THP-1 cells were seeded onto 12-well plates (1.5  105/well)
and incubated with PMA (25 ng/mL) for 48 hours to induce
differentiation. Cancer cells were labeled with carboxyﬂuorescein
succinimidyl ester (CFSE; Thermo Fisher Scientiﬁc) following the
manufacturer's protocol. For each experiment, CFSE-labeled
tumor cells (3 105) were added to macrophages and incubated
in a ﬁnal volume of 1mL serum-free medium at 37C for 2 hours.
Macrophages were stained with CD11c-APC (Thermo Fisher
Scientiﬁc) for 30 minutes. Phagocytosis was assessed by ﬂow
cytometry (BD). Nonstained and CD11c-APC–stained THP-1
cells were used for proper gating of ﬂow cytometry analysis.
Tumor xenografts and immunoﬂuorescent images
For intracranial xenografts, 8-week-old female SCID (NCI)
received 100,000 viable CD47 WT or CD47/ U87 cells in 2 mL
of PBS by stereotactic injection into the right caudate/putamen.
Mice were sacriﬁced approximately 3 to 4 weeks after implanta-
tion, and tumor volumes were estimated based on the formula:
vol ¼ (sq. root of maximum cross-sectional area)3 (23). All
animal protocols used in this study were approved by the Johns
Hopkins School of Medicine Animal Care and Use Committee.
Immunoﬂuorescent staining of tumor sections was performed
following the protocol in Wu and colleagues (24). The primary
antibodies used for immunoﬂuorescent staining were as follow-
ing: Iba-1 (Wako, ThermoFisher); iNOS (ThermoFisher); TGM2
(Cell Signaling Technology); Arginase-1 (Cell Signaling Technol-
ogy). Immunoﬂuorescent images were taken under ﬂuorescent
microscopy and analyzed using Axiovision software (Zeiss).
Fluorescent microphotographs were taken, and positive stainings
were manually counted or quantiﬁed by ImageJ (NIH).
Statistical analysis
Statistical analysis was performed using Prism software
(GraphPad). Post hoc tests included the Student t test and Tukey
multiple comparison tests as appropriate. Data are represented
as mean value  SEM, and signiﬁcance was set at P < 0.05.
Results
CD47 KO increases glioma cell phagocytosis
We employed the CRISPR-Cas9 technique to completely
knockout CD47 expression in human GBM cells to investigate
the effect of CD47 loss of function on phagocytosis and tumor
Figure 1.
Establish CD47 KO human GBM cells by
genome editing. A, Schematic graph of
genome editing strategy with two gRNAs
to knockout CD47. B, PCR product from
genomic DNA of selected clones showing
heterozygous and homozygous deletion
of CD47. C, Sanger sequencing of clone
21 showing deletion of part of the
CD47 coding sequence. D, Flow
cytometry analysis with a CD47 antibody
indicated no CD47 expression on cell
membrane in CD47/ cells.
Representative data of three
measurements. E, Immunocytostaining of
CD47 in control and CD47/ cells. Bar,
20 mm. F, CD47 KOminimally affected cell
proliferation in vitro.G, CD47 KO
decreased cell migration of clone 7, but
had no effect on clone 21 (G), n¼ 3.
H, Phagocytosis analysis of THP-1 cells
cocultured with control and CD47/
cells. I,Quantiﬁcation of phagocytosis rate
of THP-1 cells against CD47WT and
CD47/ tumor cells.  , P < 0.05 and
 , P < 0.001; n¼ 6.
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growth. Two guide RNAs (gRNA) separated by 108 bp and
designed to target the ﬁrst exon of CD47 were transfected into
U87 GBM cells (Fig. 1A). In all, approximately 20 clones were
selected and analyzed via PCR for CD47 KO using a primer pair
ﬂanking the two gRNA target sites. Clones with heterozygous
CD47deletion produced twoPCRproducts of 588 bp and480 bp,
and homozygous deletion generated one 480 bp PCR product
(Fig. 1B). Sanger sequencing conﬁrmed the homozygous deletion
of the 108 bp targetedCD47 genomic sequence in cells from clone
7 and clone 21 (CD47/, Fig. 1C). Cell surface CD47 expression
was absent in these twoCD47/ clonal lines asmeasuredbyboth
ﬂow cytometry (Fig. 1D) and immunoﬂuorescence (Fig. 1E).
Cell monolayer proliferation assays showed no signiﬁcant
difference in cell growth between CD47/ cells and CD47
wild-type (WT) control cells (Fig. 1F). Transwell migration assays
revealed that CD47 KO did not have a consistent effect on tumor
cell migration, with clone 7 CD47 KO cells migrating slower than
CD47 WT cells, but clone 21 similar to that of control (Fig. 1G).
Human monocyte cells THP-1 were differentiated into macro-
phages by PMA (25ng/mL, 48–72hours) andused to evaluate the
effect of CD47 KO on phagocytosis of U87 cell. CD47 WT and
CD47/ cells were labeled with CFSE, which covalently reacts
with amine-containing residues of intracellular proteins. Labeled
U87 cells were cocultured with differentiated THP-1 cells for 2
hours. The mixture was harvested and stained with the macro-
phage-speciﬁc antibody CD11c conjugated with allophycocyanin
(APC). Flow cytometry analysis was employed to detect CD11cþ/
CFSEþmacrophages, indicative of U87 phagocytosis. The phago-
cytosis index was calculated as the percentage of CD11cþ THP-1
cells that were also CFSEþ (red boxes in Fig. 1H and I). Cocultur-
ing U87 WT cells with THP-1 cells revealed a baseline phagocy-
tosis index of approximately 9.5%. CD47 KO increased the
Figure 2.
Effect of CD47 KO on tumor growth. A,
Representative H&E staining of xenografts derived
from control and CD47/ cells. Bar, 500 mm.
B,Quantiﬁcation of the size ofWT and CD47/
xenografts. C, Immunoﬂuorescent staining conﬁrmed
that CD47 expression was eliminated in CD47/
xenografts. Bar, 20 mm. D and E, Ki67 staining and
quantiﬁcation inWT and CD47/ xenografts.
Bar, 20 mm. F, Representative microphotographs of
H&E staining of well-demarcated margins in WT
tumors (left) and irregular CD47/ tumor margins
(right). Bar, 100 mm. G, Xenografts were
immunostained with an antibody against human
nuclear–speciﬁc antigen to show tumor margins. Bar,
200 mm. H and I, Laminin staining to show blood
vessels in control and CD47/ xenografts.
Bar, 100 mm.  , P < 0.001. In vivo experiments were
repeated once.N¼ 8 in total.
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phagocytosis index by 3–4 fold to 39% and 31% in clones 7 and
21, respectively (Fig. 1I, n¼ 6, P < 0.001). This result is consistent
with an antiphagocytosis function of CD47 expression on tumor
cells.
CD47 loss of function decreases GBM xenograft growth
We examined how CD47 KO affected GBM xenograft growth.
U87WT or CD47/ cells (100,000) were separately injected into
the caudate/putamen of Balb/c immunodeﬁcient (SCID) mice
(experiments were repeated once, n ¼ 8 total); animals were
sacriﬁced approximately 4 weeks after implantation, and brain
sections were stained with hematoxylin and eosin (H&E; Fig. 2A).
Control tumors were substantially larger with an average estimat-
ed volume of 40 mm3 compared with xenografts from CD47/
clones 21 and 7 that were approximately 5.7 mm3 and 1.3 mm3
after 4 weeks, respectively (Fig. 2B, P < 0.001). CD47 expression
was conﬁrmed to be low in tumors derived from CD47/ cells
(Fig. 2C). The proliferation rate of tumor cells was examined by
Ki67 staining, and no signiﬁcant difference between WT and
CD47/ tumors was found (48% vs. 40%, Fig. 2D and E). Closer
examination of the xenografts revealed histopathologic differ-
ences between the control and CD47/ tumors. Control tumors
displayed well-demarcated tumor margins as revealed by H&E
staining (Fig. 2F, left), and immunoﬂuorescence staining with an
anti-human nuclear–speciﬁc antigen antibody (Fig. 2G, left). In
comparison, CD47/ xenografts had very irregular margins
(Fig. 2F and G, right plots). Furthermore, when similar-sized
control and CD47/ xenografts were compared, we found fewer
blood vessels in CD47/ xenografts (Fig. 2H and I, P < 0.001),
whichmay limit tumor growth. IHC staining for cleaved caspase 3
revealed no differences in tumor cell apoptosis between control
and CD47/ xenografts (Supplementary Fig. S1A and S1B).
These ﬁndings, in conjunction with our results showing that
CD47 KO minimally affected the growth rate and migration of
U87 cells while increasingmacrophage phagocytosis of tumor cell
in vitro, led us to hypothesize that the substantial differences inWT
and CD47/ in vivo growth patterns resulted from differences in
interactions between tumor cells and innate immune cells.
CD47 loss of function recruits more TAMs
The glioma-associated innate immune system, the main con-
stituents of which are TAMs, remains intact in SCID mice. We
examined TAMs in CD47 WT and CD47/ xenografts using
speciﬁc markers. Immunoﬂuorescence staining of the general
microglial/macrophage marker Iba-1 revealed that consistent
with reports from others (25), TAMs formed a dense band
surrounding the WT tumors and appeared sparsely within the
tumors (Supplementary Fig. S2). Themorphology of TAMs in the
tumor core resembled amoeboid-like microglia/macrophages
with stout processes (Fig. 3A, top plots). In CD47/ xenografts,
the morphology of TAMs in the tumor core was similar to that of
controls, but we observed an increase in the density of TAMs in
CD47KO xenografts (Fig. 3A, bottomplots). The average number
of Iba-1þ cells per microscopic ﬁeld was 105 in CD47/ xeno-
grafts, almost 2-fold higher than that of control (Fig. 3B, P < 0.05).
CD47 antibodyhas been shown todriveM2 toM1polarization
of macrophages in vitro (26). We asked if CD47 KO induces an
increase in M1-like TAMs in GBM orthotopic xenografts. Expres-
sion of M1 marker iNOS (27) as well as M2 markers arginase 1
(Arg-1; ref. 28) and transglutaminase 2 (Tgm2; ref. 29) was
examined by immunoﬂuorescence to evaluate relative numbers
of M1 and M2 macrophages in orthotopic WT and CD47/
xenografts. We found very few cells expressing the M1 marker
iNOS in the control andCD47/ xenografts (Supplementary Fig.
Figure 3.
Distribution of TAMs in xenografts.A,Microglial/macrophage marker Iba-1 staining indicated higher density of TAMs in CD47/ xenografts. B,Quantiﬁcation of
Ibaþ cells per microscopic ﬁeld in control and CD47/ xenografts. C and D, Costaining of the M2marker Arg-1 (red) and Iba-1 (green) in xenografts and
quantiﬁcation of Arg-1þ cells per ﬁeld. E, Double staining of TAMs (Iba-1þ, green) and tumor cells (HuNuþ, red) showing host immune cells with human tumor
nuclei (arrows) in CD47/ xenografts. F, Confocal microscopic imaging of the double staining of Iba-1 and HuNu in a CD47/ xenograft showing the two
markers were from the same cells (arrows).G,Quantiﬁcation of Iba-1þ cells with HuNuþ staining per microscopic ﬁeld.  , P < 0.05; n¼ 8; bar, 20 mm.
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S3A). On the other hand, the xenografts were inﬁltrated with M2-
like TAMs as evidenced by Arg-1, which costained with Iba-1
(Fig. 3C). The average number of Arg-1þ TAMs per microscopic
ﬁeld was signiﬁcantly increased by CD47 KO, from 22 in WT
tumors to 48 in CD47/ tumors (Fig. 3D, P < 0.05). Another M2
marker TGM2also increased by approximately 3-fold inCD47/
xenografts (Supplementary Fig. S3B).
To determine if CD47 KO stimulated phagocytosis in vivo, we
costained brain sections with Iba-1 (Fig. 3E, green) and human
nuclear–speciﬁc antigen (Fig. 3E, HuNu, red). Confocal micro-
scopic analysis demonstrated the engulfment of tumor cells by
microglia/macrophages (Fig. 3F, arrows).We counted total Iba-1þ
cells and cells double labeled with Iba-1 and HuNu. In CD47/
xenografts, an average of approximately 5.1% Iba-1þ cells were
also positive for HuNu in the nuclei; in contrast, Iba-1 and HuNu
double-stained cellswere rare inWTxenografts (Fig. 3G,P<0.05).
These data suggested that CD47 KO inhibited tumor growth
by promoting phagocytosis through the recruitment of M2-like
TAMs.
CD47 KO upregulates TNC
TNC is a major ECM molecule in glioma and inﬂuences
parenchymal–tumor cell interactions (30). Immunoﬂuorescence
staining with an antibody recognizing both mouse and human
TNC revealed a dramatic increase in TNC expression in CD47/
xenografts (Fig. 4A). To determine the source of the increased
TNC, we stained tumor sections with a species-speciﬁc anti-
human TNC antibody and found a signiﬁcant increase in the
expression of human TNC in CD47/ xenografts as well (Fig. 4B
and C, P < 0.001). RT-PCR and Western blot analysis of TNC
expression in vitro conﬁrmed that CD47 KO upregulated TNC
expression by approximately 2-fold at the mRNA level, and
approximately 4- to 5-fold at the protein level (Fig. 4D and E,
P < 0.05).
Cell signaling pathways were examined to determine the
molecular mechanism by which CD47 KO increased TNC expres-
sion in GBM cells. Western blot analysis was employed to screen
alterations in AKT, MAPK, Notch, and Wnt pathways. Several
Notch pathway effectors, including Jagged-1, NOTCH1, and
Figure 4.
TNCwas upregulated in CD47/ xenografts.
A, Immunoﬂuorescence staining of TNCwith an antibody
recognizing both mouse and human TNC. B, Staining of
TNC using an antibody that only recognizes human TNC.
Bar, 100 mm. C,Quantiﬁcation of human TNC staining
intensity. D and E, RT-PCR andWestern blot analysis
conﬁrmed TNCwas upregulated at the mRNA and protein
level (Mw 200–250 KD) in CD47
/ clonal cells.
F, Signaling pathways activated in CD47/ clones. The
Notch but not Wnt and AKT pathways were elevated in
CD47/ cells. G, Jagged-1 and NOTCH1 were upregulated
by CD47 KO at the mRNA level. H,Notch pathway
inhibitor DAPT blunted TNC upregulation in CD47/ cells.
In vitro experiments were replicated at least three times.
 , P < 0.05;  , P < 0.001; n¼ 8.
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NICD, were increased 1.9- to 4.7-fold in CD47/ cells in com-
parison with WT cells (Fig. 4F). Jagged-1 and NOTCH1 mRNA
levels were also upregulated in CD47/ cells (Fig. 4G). Treating
cells with the speciﬁc Notch pathway inhibitor DAPT (N-[N-(3,5-
Diﬂurophenaacetyl-L-alanyl)]-S-phenylglycine t-Butyl Ester)
decreased TNC protein level in CD47/ cells but not in WT cells
(Fig. 4H), suggesting that Notch signaling was a driver of TNC
upregulation in the CD47/ cells.
TNC is also upregulated in mouse glioma cells with CD47 KO
To determine whether our major ﬁnding in SCID mice also
applies to immunocompetent animal models, we knocked out
Cd47 in mouse glioma GL261 cells using genome editing and
gRNAs targeting mouse Cd47 exon 2 (Supplementary Fig. S4A).
After subcloning and genotyping, we obtained GL261 cells with
CD47 KO. Shown in Supplementary Fig. S4B is the Sanger
sequencing of the PCR product from genomic DNA of GL261
clone 29with a deletion of 161 bp at theCd47 exon 2. Cell surface
CD47 expression was absent in clone 29 as measured by ﬂow
cytometry (Fig. 5A). CD47 KO did not alter GL261 proliferation
and migration. Phagocytosis analysis with THP-1 cells conﬁrmed
that CD47KO increased the phagocytosis index by approximately
2-fold from 19% to 40.1% in mouse glioma cells (Fig. 5B,
P<0.001). In immunocompetent syngeneic C57BL/6mice, CD47
KO decreased xenografts growth from 97 to 18mm3 (Fig. 5C and
D, n ¼ 5, P < 0.05). Similarly, control GL-261 tumors displayed
well-demarcated tumor margins, whereas Cd47/ tumors had
irregularmargins (Fig. 5E). Furthermore, immunostaining of TNC
in GL261 intracranial tumors indicated TNC was upregulated in
Cd47/ tumors by nearly 3-fold (Fig. 5F and G, P < 0.05), which
was conﬁrmed by Western blot analysis (3.5-fold) of GL261 cells
in vitro (Fig. 5H). This conﬁrms that our ﬁndings in human GBM
cells and SCID mice can be replicated in other model systems.
TNC knockdown abrogates the antitumor effect of CD47 KO
We hypothesized that TNC upregulation contributed to tumor
growth inhibition in CD47/ tumors. To test this, TNC expres-
sion in U87 control and CD47/ cells was knocked down using
TNC shRNA because TNC was more prominently upregulated by
CD47 loss of functions in U87 cells. TNC shRNA decreased
TNC expression by approximately 80% in both CD47 WT and
CD47/ cells relative to control cells transduced with NS shRNA
(Fig. 6A), consistent with the efﬁciency previously described by
us (20). TNC knockdown (KD) did not affect cell growth rate
in vitro (Fig. 6B).
Orthotopic tumor xenografts fromU87CD47WTandCD47/
cells with or without TNCKD were used to investigate the role of
TNC upregulation in the altered growth of CD47/ xenografts.
Animals were sacriﬁced around postimplantation day 18. H&E
stainingofbrain sections revealed that TNCKDincreased the sizeof
CD47/ xenografts from 11 to 30mm3 (Fig. 6C andD, P < 0.05).
Knocking downTNCalone inCD47WT tumor cells also increased
tumor growth from 27 to 101mm3 (P < 0.05), consistent with our
previous published work that TNC loss of function increased
tumor growth (28). The size of CD47/ þ TNC KD xenografts
was signiﬁcantly smaller than that of CD47 WT þ TNC KD,
indicating CD47 KO dramatically impairs tumor growth even
when TNC was knocked down (P < 0.05). Immunoﬂuorescence
staining conﬁrmed TNC downregulation in xenografts derived
from TNC shRNA transduced cells (Fig. 6E).
Anti–Iba-1 and anti–Arg-1 immunoﬂuorescence was used to
investigate how changes in microenvironmental TNC levels
altered interactions between TAMs and tumor cells. TNCKD
abrogated the increase in TAM recruitment induced by CD47 KO
(Fig. 6F). The average number Iba-1þ TAMs per microscopic ﬁeld
decreased from106 inCD47/þNSxenografts to 60 inCD47/
þTNCKD xenografts (Fig. 6G, P < 0.05). The number of Arg-1þ
TAMs in CD47/ xenografts, however, was not changed by
TNCKD (Supplementary Fig. S5).
TNC modulates tumor cell–immune cell interactions
Our in vivo results support a mechanism by which microenvi-
ronmental TNC mediates antitumor responses to CD47 KO.
As an extracellular protein involved in integrin binding and
Figure 5.
CD47 KO increased TNC expression in
immunocompetent mouse models. A, Flow
cytometry analysis with an anti-mouse CD47
antibody indicated no CD47 expression on cell
membrane in Cd47/ cells. B, Phagocytosis
analysis of THP-1 cells cocultured with GL261
Cd47WT and Cd47/ cells. C and D,
Representative H &E staining of tumors derived
from GL261 cells grown in syngeneic
immunocompetent mice C56BL/6. Bar, 500 mm.
E, H&E staining of well-demarcated margins in
WT tumors (left) and irregular Cd47/ tumor
margins (right) in immunocompetent mice. Bar,
100 mm. F, Immunostaining showed TNC was
upregulated in Cd47/ tumor. Bar, 100 mm.
G,Quantiﬁcation of intensity of TNC in GL261
tumors. H,Western blot analysis conﬁrmed that
TNCwas upregulated in CD47 KO GL261 cells.
 , P < 0.05;  , P < 0.001; n¼ 4.
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cytoskeleton regulation (31, 32), we hypothesized that this func-
tion of TNC reﬂected changes in tumor cell phagocytosis by TAMs.
Indeed, we found TNCKD inhibited phagocytosis triggered by
CD47 KO in vitro (Fig. 7A). As shown before, CD47 KO increased
phagocytosis of control U87 cells by approximately 3- to 4-fold,
from 15.2% to 49.1%. TNCKD signiﬁcantly decreased phagocy-
tosis induced by CD47KO from49.1% to 28% (Fig. 7B, P < 0.05).
We also noticed that compared with U87 CD47WT cells, TNCKD
decreased the baseline phagocytosis from 15.2% to 8.1%, which
may partially explain the increased tumor size from CD47 WT
þTNCKD cells. Our ﬁndings suggest that elevated expression of
TNC in CD47/ cells promoted phagocytosis, and TNC expres-
sion in tumor cells could contribute to baseline phagocytosis
independent of CD47.
Because TNC is upregulated in response to inﬂammation (33),
we hypothesized that TNC may elicit other immunomodulation
functions to facilitate tumor cell–immune cell interactions. To
this end, we studied TNC gain of function using exogenous TNC.
THP-1 cells were treated with human TNC (1–10 mg/mL) for 8
hours followed by RT-PCR to measure the expression level of
several proinﬂammatory factors including IL1b, IL6, and TNFa.
Cells treated with lipopolysaccharides (LPS) were used as a
positive control. Real-time quantitative RT-PCR revealed a con-
centration-dependent upregulation of these proinﬂammatory
Figure 6.
The effect of TNC loss of function on the antitumor
function of CD47 KO.A, Knocking down TNC
expression inWT cells and clone 21 CD47/ cells
using TNC-speciﬁc shRNA (TNCKD). NS shRNA
was used as a control. B,Growth curve of TNCKD
cells in comparison with their counterparts. C, H&E
staining of xenografts derived from CD47WT and
CD47/ cells harboring TNCKD. Bar, 500 mm.
D,Quantiﬁcation of tumor size. E, Staining of
human-speciﬁc TNC conﬁrmed TNC
downregulation in xenografts derived from cells
receiving TNC shRNA. Bar, 100 mm. F, Staining of
the microglial/macrophage marker Iba-1 in TNCKD
xenografts. Bar, 20 mm. G,Quantiﬁcation of the
number of Iba-1þ cells in control and CD47/
xenografts with and without TNCKD. TNCKD
decreased Iba1þ cells in CD47/ xenografts.
 , P < 0.05; n¼ 5.
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factors (Fig. 7C, P < 0.05). ELISA of THP-1 conditioned medium
revealed concentration-dependent increase in TNFa production
driven by TNC (Fig. 7D, P < 0.05). We performed IHC staining of
TNFa in CD47 WT  NS and CD47/  TNCKD xenografts.
Consistent with our in vitro studies, our in vivo staining indicated
that CD47 KO increased TNFa staining by 63%, which was
Figure 7.
Effect of TNC on phagocytosis and macrophage
cells. A, TNCKD in tumor cells decreased
phagocytosis of WT and CD47/ cells by
macrophages. B,Quantiﬁcation of phagocytosis,
n¼ 3. C, RT-PCR indicated that exogenous TNC
induced expression of proinﬂammatory genes
including IL1b, IL6, and TNFa in THP-1 cells in a
dose-dependent manner. LPS was used as a
positive control, n¼ 6. D, ELISA showed TNC
increased TNFa secretion in THP-1 cells in a dose-
dependent manner. n¼ 3. E, IHC staining of TNFa
in CD47WT NS and CD47/  TNCKD
xenografts. Methyl green (green) was used to
counterstain nuclei. Bar, 20 mm. F,Quantiﬁcation of
percentage of cells with TNFa staining in the
xenografts. n¼ 5. G, Immunoblot analysis indicated
that TNC treatment activated STAT3 in THP-1 cells,
which was blocked by the STAT3 inhibitor stattic.
H, Stattic prevented TNFa production in THP-1 cells
treated with TNC. n¼ 3. I, TLR4 inhibitor TAK242
blocked STAT3 activation in THP-1 cells in response
to TNC. J, TAK242 decreased TNC-induced TNFa
production in THP-1 cells. n¼ 3. , P < 0.05.
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reversed when TNC was knocked down (Fig. 7E and F, P < 0.05).
This result indicated that TNCupregulation driven byCD47KO is
involved in the increased cytokine production.
STAT3 was activated in THP-1 cells following TNC treatment
(Fig. 7G). The STAT3-speciﬁc inhibitor stattic (5 mmol/L) pre-
vented STAT3 activation in TNC-treated THP-1 cells and inhibited
TNFa production induced by TNC (Fig. 7H, P < 0.05). Preincu-
bating THP-1 cells with the Toll-like receptor 4 (TLR4) inhibitor
TAK242 (10 mmol/L) also inhibited TNC-induced STAT3 activa-
tion andTNFaproduction (Fig. 7I and J,P<0.05). Taken together,
our results indicated that the ECM protein TNC activated STAT3
and induced the secretion of proinﬂammatory factors in macro-
phage cells, which may explain the systemically increased recruit-
ment of TAMs in CD47/ xenografts.
Discussion
In this work, we established CD47 loss of function in GBM
cells to investigate the impact of eliminating the "don't eat me"
signal on tumor growth and tumor–TME interactions. CD47
KO signiﬁcantly decreased intracranial tumor growth by
recruiting more M2-like TAMs and inducing phagocytosis. We
found that CD47 KO in glioma cells upregulated the ECM
protein TNC in vitro and in both SCID mice and immunocom-
petent mice. Knocking down TNC expression in tumor cells
reversed CD47 KO-mediated phagocytosis in vitro and its anti-
tumor effect in vivo. We also found TNC may elicit a systematic
immunomodulation role via binding to TLR4 in macrophages
to activate STAT3 and stimulate release of proinﬂammatory
factors including TNFa. To the best of our knowledge, this is the
ﬁrst study to link TNC to CD47-mediated phagocytosis signal-
ing and demonstrate the importance of TNC in affecting the
antitumor function of brain TAMs.
Our in vitro and in vivo phagocytosis analyses of CD47 KO cells
are consistent with previous studies by others demonstrating that
targeting the CD47–SIRPa axis with speciﬁc blocking antibody
increases phagocytosis (12–14). CD47 is amultifacetedmolecule
that interacts with many receptors/ligands to mediate a variety of
biological functions. Our data suggest that apart from the "don't
eat me" signaling pathway, CD47 KO also affects other pathways
and molecules. It has been reported that CD47 serves as the
receptor for matricellular protein TSP-1, a prototype of the matri-
cellular protein family with members like TNC and secreted
protein acidic and rich in cysteine (SPARC). TSP-1 is implicated
in angiogenesis, which may explain changes in laminin staining
observed in CD47/ xenografts. Our data also found that TNC
was upregulated by CD47 KO via a Notch-mediated mechanism,
consistent with report from Sivasankaran and colleagues that the
activation of the Notch pathway increased TNC expression (34).
Kaur and colleagues reported that CD47 knockdown leads to
c-Myc activation and stem cell marker expression such as KLF4,
OCT 4, and Sox2 (16). In GBM, the Notch pathway has been
implicated in GBM stem cell biology (35). Therefore, it is tempt-
ing to speculate that CD47 KOupregulates theNotch pathway via
alteration in stem cell–related pathways. On the other hand,
studies from Sarkar and colleagues indicated Notch activation is
downstream of TNC signaling in brain tumor stem cells (36). A
detailed link between CD47 KO and TNC is currently under
investigation.
In immunodeﬁcient mice (SCID), the adaptive immune sys-
tem, including T cells and B cells, is deﬁcient; whereas the innate
immune system, including microglia, macrophage, and natural
killer cells, remains intact (37). The size of CD47/ xenografts
was much smaller compared with that of control, yet the number
of inﬁltrating TAMs in CD47/ xenografts was signiﬁcantly
higher than that of control. We reasoned that phagocytosis/
cytotoxicity mediated by TAMs was the main contributor of the
decreased tumor size in CD47/ xenografts, because our in vitro
analysis showednogrowthdifference betweenCD47WTcells and
CD47/ cells. Our in vivo Ki67 staining further conﬁrmed this.
Thus, depending on the TME, high TAM density was not always
associated with more aggressive tumors. Works from Loane and
colleagues (38) indicated that TAMs with amoeboid-like shape
were motile, whereas the hypertrophic morphology of TAMs
was associated with a phagocytic activity. In our models, the
morphology of TAMs in CD47/ xenografts was similar to that
of controls with amoeboid-like shape. The increased density of
Arg-1þ in CD47/ xenografts suggested that more M2-like
TAMs were recruited by CD47 KO xenografts. Although Zhang
and colleagues reported that anti-CD47 antibody repolarized
M2 macrophage to M1 macrophage (26), we did not observe
such repolarization of TAMs following CD47 KO in our mod-
els. However, we were able to demonstrate the increased
phagocytosis ability of TAMs in CD47/ xenografts by double
staining of human nuclei and Iba-1 in TAMs, consistent with
studies for Leidi and colleagues demonstrating that M2-like
TAMs also have phagocytic ability (39).
Compared with U87 WT xenografts that always form ball-like
solid tumors, the histopathologic features of CD47KO xenografts
show invasive margin of xenografts. This could be either from the
increased phagocytosis by inﬁltrating microglia/macrophages or
increased tumor cell migration due to high TNC level. Because the
effect of CD47 KO on tumor cell migration was not consistent in
different clones, we reason that the increased phagocytosismay be
the main cause for the dramatic change in the histopathologic
features of CD47 KO xenografts.
One of the interesting ﬁndings in this study is to link TNC as a
modulator of phagocytosis in brain cancer. Our ﬁndings are in
line with works regarding TNC function in the periphery sys-
tem (40, 41). TNC is one of the most abundant ECM proteins in
the brain TME, and its expression correlates with GBM progres-
sion. Our ﬁndings that TNCwas upregulated following CD47 KO
and plays a beneﬁcial role to facilitate phagocytosis are counter-
intuitive but not surprising as we have previously reported that
targeting TNC in GBM stem-like neurosphere cells inhibited
tumor migration but promoted tumor growth in vivo (20). As a
consequence of its complex structure, TNC functions as an ECM
molecule to activate the integrin signaling pathway during adhe-
sion,migration, and cytoskeleton rearrangement, whichmay also
contribute to increasedphagocytosis inCD47/ xenografts as the
phagocytosis process employs cytoskeleton such as myosin to
form phagocytosis cup. Besides this, we also found that TNCmay
elicit a systematic role to facilitate phagocytosis by inducing
proinﬂammatory factors, which may recruit more immune cells
to attack tumor cells. It has been well-documented that TNC is
upregulated during inﬂammation and plays an important role in
wound healing (42, 43). In arthritic joint diseases, TNC has been
reported to function as an endogenous activator of TLR4 via its
ﬁbrinogen-like domain to induce inﬂammation (43). Our results
of TNC function in brain tumor are consistentwith the function of
TNC in the periphery system. With the ﬁndings that TNC is
dramatically upregulated in CD47/ xenografts and modulates
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phagocytosis, it is appealing to think that instead of being a
promoter of tumormalignancy, the elevated TNC in brain tumors
may be a defensive mechanism by the innate system to try to
eliminate malignant cells.
Over thepast years, the useof immune-checkpoint inhibitors to
target the adaptive immune systems has been one of the most
signiﬁcant advances in antitumor treatment. However, the
increased use of these agents has led to an augmented apprecia-
tion that theywerenot suitable for all patients. Recent studies have
indicated that the innate immune system checkpoint such as
CD47 may be an interesting therapeutic target (44). A better
mechanistic understanding of CD47 signaling network will aid
in the development of novel antitumor reagent. Our study pro-
vides the ﬁrst evidence demonstrating that microenvironmental
TNC is involved in phagocytosis of tumor cell by TAMs. Future
studies of the precise mechanism by which TNC regulates phago-
cytosis will shed light on how to exploit the innate immune
system to target brain tumors.
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